Cardiovascular drugs and therapy

Keyphrases

Publications

2024

Na Li, Mihail G Chelu, Yochai Birnbaum
Dapagliflozin for Atrial Fibrillation. Cardiovascular drugs and therapy (2024)
Jeffrey B Booker, Alexander J Nihart, Matthew J Campen, Eduardo Medrano-Rodriguez, James C Blankenship
Discharge of Acute Coronary Syndrome Patients on Sub-Optimal Dual Anti-Platelet Therapy: A Single Center Experience. Cardiovascular drugs and therapy (2024)
Yongsheng Liu, Man Jiang, Meitian Zhang, Yawen Xie, Lixin Wang, Pilong Shi, Qianlong Zhang, Qianhui Zhang, Kai Liu, Jiajun Zhou, Chao Song, Hongli Sun
LncRNA Gm15834 Aggravates Cardiac Hypertrophy by Interacting with Sam68 and Activating NF-κB Mediated Inflammation. Cardiovascular drugs and therapy (2024)
Sylwia L Sławek-Szmyt, Aleksander Araszkiewicz, Stanisław Jankiewicz, Marek Grygier, Tatiana Mularek-Kubzdela, Maciej Lesiak
Outcomes With Hybrid Catheter-Directed Therapy Compared With Aspiration Thrombectomy for Patients With Intermediate-High Risk Pulmonary Embolism. Cardiovascular drugs and therapy (2024)
Shannon Clay, James C Blankenship
Left Ventricular Thrombus After Myocardial Infarction: Opinions and Equipoise. Cardiovascular drugs and therapy (2024)
Saifei Liu, Indy Aj Lawrie, Bibi Rabia, Chukwudiebube N Ajaero
Impairment of Vascular Homeostasis in Acute Heart Failure: Enter the Monocyte? Cardiovascular drugs and therapy (2024)
Jonathan Ka-Ming Ho, Hon-Lon Tam, Leona Yuen-Ling Leung
Effectiveness of Vasopressin Against Cardiac Arrest: A Systematic Review of Systematic Reviews. Cardiovascular drugs and therapy (2024)
Jun Gu, Zhi-Hua Han, Chang-Qian Wang, Jun-Feng Zhang
The Impacts of Nirmatrelvir-Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic. Cardiovascular drugs and therapy (2024)
Xiaodi Zhang, Yi Zhao, Dafen Guo, Mingxian Luo, Qing Zhang, Li Zhang, Dengshen Zhang
Exercise Improves Heart Function after Myocardial Infarction: The Merits of AMPK. Cardiovascular drugs and therapy (2024)
Sa Liu, Jiaqin Liu, Nan Su, Shanshan Wei, Ning Xie, Xiangyun Li, Suifen Xie, Jian Liu, Bikui Zhang, Wenqun Li, Shengyu Tan
An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity. Cardiovascular drugs and therapy (2024)
Yating Xu, Di Xia, Shan Deng, Minglu Liang
Isoimperatorin Inhibits Angiogenesis by Suppressing VEGFR2 Signaling Pathway. Cardiovascular drugs and therapy (2024)
Shichao Wei, Feng Ju, Junshen Xiao, Jiaxue Li, Ting Liu, Zhaoyang Hu
Aloperine Alleviates Myocardial Injury Induced by Myocardial Ischemia and Reperfusion by Activating the ERK1/2/β-catenin Signaling Pathway. Cardiovascular drugs and therapy (2024)
Hani Sabbour, Deepak L Bhatt, Yaser Elhenawi, Asma Aljaberi, Layal Bennani, Tarek Fiad, Khwaja Hasan, Shahrukh Hashmani, Rabih A Hijazi, Zafar Khan, Ronney Shantouf
A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. Cardiovascular drugs and therapy (2024)
Ian S deSouza, Pragati Shrestha, Robert Allen, Jessica Koos, Henry Thode
Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis. Cardiovascular drugs and therapy (2024)
Maurizio Giuseppe Abrignani, Edoardo G Gronda, Marco Marini, Michele Senni, Massimo Iacoviello, Pier Luigi Temporelli, Manuela Benvenuto, Giulio Binaghi, Arturo Cesaro, Alessandro Maloberti, Maria Denitza Tinti, Carmine Riccio, Furio Colivicchi, Massimo Grimaldi, Domenico Gabrielli, Fabrizio Oliva, null null
Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem. Cardiovascular drugs and therapy (2024)
Shin Ito, Yuri Nakajima, Hiroki Fukuda, Chisato Izumi, Gaku Nakazawa, Hajime Yamashita, Hideo Matsuhisa, Moriaki Inoko, Shigeru Toyoda, Shin Takiuchi, Toru Kataoka, Yasuhiro Izumiya, Yukio Abe, Takashi Sozu, Yasushi Sakata, Masanori Emoto, Teruo Inoue, Masafumi Kitakaze
Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial). Cardiovascular drugs and therapy (2024)
Kai-Yuan Chen, Zhou Liu, Jun-Hou Lu, Si-Yuan Yang, Xuan-Yi Hu, Gui-You Liang
The Function of Circular RNAs in Myocardial Ischemia-Reperfusion Injury: Underlying Mechanisms and Therapeutic Advancement. Cardiovascular drugs and therapy (2024)
Rongyuan Yang, Qingqing Liu, Dawei Wang, Zhen Zhao, Zhaohai Su, Daping Fan, Qing Liu
The Toll-like Receptor-2/4 Antagonist, Sparstolonin B, and Inflammatory Diseases: A Literature Mining and Network Analysis. Cardiovascular drugs and therapy (2024)
Boxiang Wang, Yidin Xu, Yilun Huang, Siming Shao, Dongshan Xu, Yiying Zhang, Lingxia Pang, Zhuofan Nan, Qianxi Ye, Yang Wang, Wantie Wang, Keke Jin, Linbo Yuan
miR-210-5p Promotes Pulmonary Hypertension by Blocking ATP2A2. Cardiovascular drugs and therapy (2024)
Mark Sahyouni, George A Stouffer
Instent CTO-What Is the Best Treatment Strategy? Cardiovascular drugs and therapy (2024)
Spencer Ng, Kevin Friede, George A Stouffer
The Case Continues to Build: More Data that Intracoronary Thrombolysis Is Safe and Effective in STEMI. Cardiovascular drugs and therapy (2024)
Francesco Condello, Angelica Cersosimo, Riccardo Cappato, Paolo Pagnotta
Open Issues in the Management of Otcagerian Patients with Atrial Fibrillation and Chronic Kidney Disease: Are we Ready for Left Atrial Appendage Occlusion (LAAO) as First-Line Therapy for Thromboembolic Risk Prevention? Cardiovascular drugs and therapy (2024)
Mohamed Nabil Elshafei, Muhammad Salem, Ahmed El-Bardissy, Mohamed S Abdelmoneim, Ahmed Khalil, Sherine Elhadad, Mutasem Al Mistarihi, Mohammed Danjuma
Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Low Body Weight Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis. Cardiovascular drugs and therapy (2024)
Yuan Xue, Shipan Wang, Xuehuan Zhang, Xiaomeng Wang, Yue Shi, Hongjia Zhang, Duanduan Chen, Haiyang Li
Surgical Treatment for Type A Aortic Dissection after Endovascular Aortic Repair: A 12-year, Single-Center Study. Cardiovascular drugs and therapy (2024)
András Nagy, Denise Börzsei, Alexandra Hoffmann, Szilvia Török, Médea Veszelka, Nikoletta Almási, Csaba Varga, Renáta Szabó
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms. Cardiovascular drugs and therapy (2024)
Robert S Rosenson, Daniel J Rader, Shazia Ali, Poulabi Banerjee, Jennifer McGinniss, Robert Pordy
Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials. Cardiovascular drugs and therapy (2024)
Vincenzo Russo, Eleonora Caiazza, Fiorella Chiara Delle Femine, Enrica Pezzullo, Sara Sarpa, Antonio Ianniciello, Caturano Alfredo, Antonello D'Andrea, Paolo Golino, Gerardo Nigro
Predictors of Plasma Levels of Direct Oral Anticoagulants Among Patients with Atrial Fibrillation in Need of Elective Cardiac Procedures. Cardiovascular drugs and therapy (2024)
Jeffrey B Booker, Alexander J Nihart, Matthew J Campen, Eduardo Medrano-Rodriguez, James C Blankenship
Discharge of Acute Coronary Syndrome Patients on Sub-Optimal Dual Anti-Platelet Therapy: A Single Center Experience. Cardiovascular drugs and therapy (2024)
Lixiao Hang, Ying Zhang, Zheng Zhang, Haiqiang Jiang, Lin Xia
Metabolism Serves as a Bridge Between Cardiomyocytes and Immune Cells in Cardiovascular Diseases. Cardiovascular drugs and therapy (2024)
Mahsa Mansourian, Zahra Teimouri-Jervekani, Azam Soleimani, Rasool Nouri, Hamidreza Marateb, Marjan Mansourian
Changes in Heart Rate Variability Parameters Following Radiofrequency Ablation in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiovascular drugs and therapy (2024)
Yanyan Ye, Fangyuan Chang, Yingchun Xu
IL-33 in Atherosclerosis: An Insufficiently Explored and Controversial Research Area. Cardiovascular drugs and therapy (2024)
Gary Tse, Sharen Lee, Tong Liu, Jiandong Zhou
Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study. Cardiovascular drugs and therapy (2024)
Jorge A Irizarry-Caro, Juhee Song, Chase Miller, Shyam Desai, James Going, Jose Fossas-Espinosa, Mariya M Fatakdawala, Abdelrahman Ali, Cezar Iliescu, Nicolas Palaskas, Anita Deswal, Efstratios Koutroumpakis
Evaluation of Midodrine Utilization in Patients with Cancer and Heart Failure. Cardiovascular drugs and therapy (2024)
Daniel A Gomes, João Presume, Pedro de Araújo Gonçalves, Manuel Sousa Almeida, Miguel Mendes, Jorge Ferreira
Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials. Cardiovascular drugs and therapy (2024)
Chang Di, Meng Ji, Wenjin Li, Xiaoyi Liu, Rijan Gurung, Boyang Qin, Shu Ye, Rong Qi
Pyroptosis of Vascular Smooth Muscle Cells as a Potential New Target for Preventing Vascular Diseases. Cardiovascular drugs and therapy (2024)
Seo-A Choi, Jung Sun Kim, Yoon-A Park, Da Hoon Lee, Minju Park, Jeong Yee, Yoonkyung Chang, Tae-Jin Song, Hye Sun Gwak
Transporter Genes and statin-induced Hepatotoxicity. Cardiovascular drugs and therapy (2024)
Wei Wang, Xinyi Yang, Yumeng Hu, Xiaochang Leng, Jianping Xiang, Xianhe Lin
Angiography-based Fractional Flow Reserve for the Prediction of Clinical Outcomes After Drug-coated Balloon or Plain Old Balloon Angioplasty. Cardiovascular drugs and therapy (2024)

volume 38, number 1, 2024

Na Li, Mihail G Chelu, Yochai Birnbaum
Dapagliflozin for Atrial Fibrillation. Cardiovascular drugs and therapy 38 (1) (2024)
Na Li, Mihail G Chelu, Yochai Birnbaum
Dapagliflozin for Atrial Fibrillation. Cardiovascular drugs and therapy 38 (1) (2024)

volume 38, number 2, 2024

Spencer Ng, Kevin Friede, George A Stouffer
The Case Continues to Build: More Data that Intracoronary Thrombolysis Is Safe and Effective in STEMI. Cardiovascular drugs and therapy 38 (2) (2024)
Gary Tse, Sharen Lee, Tong Liu, Jiandong Zhou
Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study. Cardiovascular drugs and therapy 38 (2) (2024)
Spencer Ng, Kevin Friede, George A Stouffer
The Case Continues to Build: More Data that Intracoronary Thrombolysis Is Safe and Effective in STEMI. Cardiovascular drugs and therapy 38 (2) (2024)
Gary Tse, Sharen Lee, Tong Liu, Jiandong Zhou
Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study. Cardiovascular drugs and therapy 38 (2) (2024)

volume 38, number 3, 2024

Yanyan Ye, Fangyuan Chang, Yingchun Xu
IL-33 in Atherosclerosis: An Insufficiently Explored and Controversial Research Area. Cardiovascular drugs and therapy 38 (3) (2024)
Saifei Liu, Indy Aj Lawrie, Bibi Rabia, Chukwudiebube N Ajaero
Impairment of Vascular Homeostasis in Acute Heart Failure: Enter the Monocyte? Cardiovascular drugs and therapy 38 (3) (2024)
Yanyan Ye, Fangyuan Chang, Yingchun Xu
IL-33 in Atherosclerosis: An Insufficiently Explored and Controversial Research Area. Cardiovascular drugs and therapy 38 (3) (2024)
Mark Sahyouni, George A Stouffer
Instent CTO-What Is the Best Treatment Strategy? Cardiovascular drugs and therapy 38 (3) (2024)
Francesco Condello, Angelica Cersosimo, Riccardo Cappato, Paolo Pagnotta
Open Issues in the Management of Otcagerian Patients with Atrial Fibrillation and Chronic Kidney Disease: Are we Ready for Left Atrial Appendage Occlusion (LAAO) as First-Line Therapy for Thromboembolic Risk Prevention? Cardiovascular drugs and therapy 38 (3) (2024)

volume 38, number 4, 2024

Faiz Moin Baqai, Masafumi Kitakaze, Yochai Birnbaum
Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice? Cardiovascular drugs and therapy 38 (4) (2024)
Shannon Clay, James C Blankenship
Left Ventricular Thrombus After Myocardial Infarction: Opinions and Equipoise. Cardiovascular drugs and therapy 38 (4) (2024)